Serelaxin Works for the Treatment of Acute Heart Failure


Serelaxin FDA Breakthrough Therapy StatusPositive studies of the recombinant human relaxin-2, known as Serelaxin, have continued to emerge, offering excitement in the pharmaceutical arena. On October 25, 2013 study data published on Medscape via The Lancet revealed the most recent data from a randomized and placebo controlled trial. This trial, coined RELAX-AHF, aimed to test the hypothesis that patients treated with Serelaxin for acute heart failure would glean better relief from dyspnoea symptoms when compared with patients treated with the best standard care and a placebo. Of the 1.161 patients enrolled in the RELAX-AHF study 581 were assigned randomly to receive Serelaxin, while the other 580 participants were randomly chosen to receive a placebo.  Results from the RELAX-AHF trial supported the use of Serelaxin, showing a sizable improvement in dyspnoea relief for patients who received this vasoactive peptide hormone, as compared to the participants who received a placebo. The mortality rate was also markedly improved in the patient population who received Serelaxin as compared to the placebo group. Additionally, no serious adverse effects were found from the patients who were administered Serelaxin, with the majority of patients finding this novel treatment tolerable.

Previous studies of Serelaxin, which is marketed by Novartis, have also revealed positive results. Data presented at the American Heart Association annual meeting in late 2012 offered significant statistics supporting the use of Serelaxin for treating patients with acute heart failure. One statistic extrapolated from study data showed that Serelaxin reduced patients’ deaths by 37 percent when administered to participants hospitalized with acute heart failure (AHF).  Another uplifting statistic garnished from prior studies documented that patients who received a continuous intravenous infusion of Serelaxin for 48 hours experienced 45 percent less episodes of worsening heart failure symptoms.

Breakthrough Therapy status was granted to Serelaxin on June 21, 2013 from the FDA. LGM Pharma provides the Serelaxin CAS# 99489-94-8 API for research and development purposes. Clients can be assured of continuous support throughout the R&D process, as well as quality API products.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

 

  • Share: